<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101061</url>
  </required_header>
  <id_info>
    <org_study_id>20090378</org_study_id>
    <nct_id>NCT01101061</nct_id>
  </id_info>
  <brief_title>A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the safety, tolerability and potential immune
      response to romosozumab following single subcutaneous (SC; injection under the skin) dose
      administration in healthy postmenopausal Japanese and non-Japanese women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2010</start_date>
  <completion_date type="Actual">November 1, 2010</completion_date>
  <primary_completion_date type="Actual">November 1, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments.</time_frame>
    <description>A serious adverse event (SAE) is defined as an adverse event that
is fatal
is life threatening
requires in-patient hospitalization or prolongation of existing hospitalization
results in persistent or significant disability/incapacity
is a congenital anomaly/birth defect
other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Developed Anti-romosozumab Binding Antibodies</measure>
    <time_frame>Day 29, and end of study (day 57 for participants assigned to 1 or 3 mg/kg romosozumab/placebo or day 85 for participants assigned to 5 mg/kg romosozumab/placebo)</time_frame>
    <description>Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Calcium Levels</measure>
    <time_frame>Baseline, days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Intact Parathyroid Hormone (iPTH) Levels</measure>
    <time_frame>Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)</measure>
    <time_frame>Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)</measure>
    <time_frame>Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Sclerostin</measure>
    <time_frame>Baseline and days 12, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration of Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration of Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab</measure>
    <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
    <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Romosozumab</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese subjects must be first (4 grandparents, biologic parents and subject born in
             Japan), second (4 grandparents and biological parents born in Japan) or third (4
             grandparents born in Japan) generation Japanese

          -  Body mass index ≤ 25 kg/m², inclusive at screening

          -  Postmenopausal females defined as 12 continuous months of spontaneous amenorrhea
             confirmed by a serum follicle-stimulating hormone (FSH) result &gt; 40 mIU/mL, or 6 weeks
             postsurgical bilateral oophorectomy (with or without hysterectomy) as documented in
             medical history (verified with an operative note, if available)

        Exclusion Criteria:

          -  Osteoporosis, as defined by bone mineral density (BMD) T-scores of the lumbar spine
             (L1-L4) or total evaluable vertebrae (if fewer than L1-L4); or femoral neck ≤ -2.5

          -  History of vertebral fracture or fragility fracture of the wrist, humerus, hip or
             pelvis;

          -  Diagnosed with any condition that will affect bone metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <results_first_submitted>April 10, 2019</results_first_submitted>
  <results_first_submitted_qc>July 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2019</results_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 2 study centers in the United States. Eligible participants were healthy, postmenopausal first, second, or third generation Japanese women and non-Japanese women residing in the United States.</recruitment_details>
      <pre_assignment_details>Participants were assigned to one of 4 cohorts. In 3 of the cohorts Japanese women were randomized in a 3:1 ratio to receive 1, 3, or 5 mg/kg romosozumab or placebo. In a 4th cohort non-Japanese women were randomized in a 2:1 ratio to receive 3 mg/kg romosozumab or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Japanese Women: Placebo</title>
          <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
        </group>
        <group group_id="P2">
          <title>Japanese Women: Romosozumab 1 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="P3">
          <title>Japanese Women: Romosozumab 3 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="P4">
          <title>Japanese Women: Romosozumab 5 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="P5">
          <title>Non-Japanese Women: Placebo</title>
          <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
        </group>
        <group group_id="P6">
          <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
          <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated participants</population>
      <group_list>
        <group group_id="B1">
          <title>Japanese Women: Placebo</title>
          <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
        </group>
        <group group_id="B2">
          <title>Japanese Women: Romosozumab 1 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="B3">
          <title>Japanese Women: Romosozumab 3 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="B4">
          <title>Japanese Women: Romosozumab 5 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="B5">
          <title>Non-Japanese Women: Placebo</title>
          <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
        </group>
        <group group_id="B6">
          <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
          <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="5.7"/>
                    <measurement group_id="B2" value="59.3" spread="4.9"/>
                    <measurement group_id="B3" value="61.7" spread="3.0"/>
                    <measurement group_id="B4" value="59.7" spread="7.7"/>
                    <measurement group_id="B5" value="57.5" spread="3.5"/>
                    <measurement group_id="B6" value="55.0" spread="4.8"/>
                    <measurement group_id="B7" value="59.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>A serious adverse event (SAE) is defined as an adverse event that
is fatal
is life threatening
requires in-patient hospitalization or prolongation of existing hospitalization
results in persistent or significant disability/incapacity
is a congenital anomaly/birth defect
other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.</description>
        <time_frame>Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>A serious adverse event (SAE) is defined as an adverse event that
is fatal
is life threatening
requires in-patient hospitalization or prolongation of existing hospitalization
results in persistent or significant disability/incapacity
is a congenital anomaly/birth defect
other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Anti-romosozumab Binding Antibodies</title>
        <description>Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.</description>
        <time_frame>Day 29, and end of study (day 57 for participants assigned to 1 or 3 mg/kg romosozumab/placebo or day 85 for participants assigned to 5 mg/kg romosozumab/placebo)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-romosozumab Binding Antibodies</title>
          <description>Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Calcium Levels</title>
        <time_frame>Baseline, days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All treated participants; only participants in the 5 mg/kg cohort were assessed at days 71 and 85.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium Levels</title>
          <population>All treated participants; only participants in the 5 mg/kg cohort were assessed at days 71 and 85.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.04"/>
                    <measurement group_id="O2" value="2.31" spread="0.04"/>
                    <measurement group_id="O3" value="2.33" spread="0.03"/>
                    <measurement group_id="O4" value="2.38" spread="0.03"/>
                    <measurement group_id="O5" value="2.28" spread="0.08"/>
                    <measurement group_id="O6" value="2.45" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.04"/>
                    <measurement group_id="O2" value="2.34" spread="0.03"/>
                    <measurement group_id="O3" value="2.31" spread="0.03"/>
                    <measurement group_id="O4" value="2.36" spread="0.03"/>
                    <measurement group_id="O5" value="2.34" spread="0.04"/>
                    <measurement group_id="O6" value="2.40" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.05"/>
                    <measurement group_id="O2" value="2.36" spread="0.04"/>
                    <measurement group_id="O3" value="2.31" spread="0.03"/>
                    <measurement group_id="O4" value="2.38" spread="0.03"/>
                    <measurement group_id="O5" value="2.34" spread="0.01"/>
                    <measurement group_id="O6" value="2.43" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.05"/>
                    <measurement group_id="O2" value="2.31" spread="0.03"/>
                    <measurement group_id="O3" value="2.30" spread="0.03"/>
                    <measurement group_id="O4" value="2.32" spread="0.03"/>
                    <measurement group_id="O5" value="2.38" spread="0.02"/>
                    <measurement group_id="O6" value="2.36" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.05"/>
                    <measurement group_id="O2" value="2.30" spread="0.03"/>
                    <measurement group_id="O3" value="2.31" spread="0.04"/>
                    <measurement group_id="O4" value="2.35" spread="0.04"/>
                    <measurement group_id="O5" value="2.28" spread="0.02"/>
                    <measurement group_id="O6" value="2.40" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.05"/>
                    <measurement group_id="O2" value="2.25" spread="0.02"/>
                    <measurement group_id="O3" value="2.31" spread="0.03"/>
                    <measurement group_id="O4" value="2.29" spread="0.03"/>
                    <measurement group_id="O5" value="2.35" spread="0.00"/>
                    <measurement group_id="O6" value="2.38" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.06"/>
                    <measurement group_id="O2" value="2.27" spread="0.05"/>
                    <measurement group_id="O3" value="2.33" spread="0.03"/>
                    <measurement group_id="O4" value="2.28" spread="0.02"/>
                    <measurement group_id="O5" value="2.33" spread="0.03"/>
                    <measurement group_id="O6" value="2.28" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.03"/>
                    <measurement group_id="O2" value="2.31" spread="0.03"/>
                    <measurement group_id="O3" value="2.28" spread="0.05"/>
                    <measurement group_id="O4" value="2.25" spread="0.03"/>
                    <measurement group_id="O5" value="2.33" spread="0.00"/>
                    <measurement group_id="O6" value="2.36" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.03"/>
                    <measurement group_id="O2" value="2.30" spread="0.04"/>
                    <measurement group_id="O3" value="2.28" spread="0.03"/>
                    <measurement group_id="O4" value="2.30" spread="0.02"/>
                    <measurement group_id="O5" value="2.36" spread="0.04"/>
                    <measurement group_id="O6" value="2.38" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.04"/>
                    <measurement group_id="O2" value="2.33" spread="0.03"/>
                    <measurement group_id="O3" value="2.28" spread="0.03"/>
                    <measurement group_id="O4" value="2.34" spread="0.04"/>
                    <measurement group_id="O5" value="2.30" spread="0.07"/>
                    <measurement group_id="O6" value="2.34" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.03"/>
                    <measurement group_id="O2" value="2.32" spread="0.04"/>
                    <measurement group_id="O3" value="2.29" spread="0.04"/>
                    <measurement group_id="O4" value="2.30" spread="0.03"/>
                    <measurement group_id="O5" value="2.28" spread="0.00"/>
                    <measurement group_id="O6" value="2.31" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.01"/>
                    <measurement group_id="O4" value="2.39" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.01"/>
                    <measurement group_id="O4" value="2.35" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Intact Parathyroid Hormone (iPTH) Levels</title>
        <time_frame>Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All treated participants; only participants in the 5 mg/kg cohort were assessed at days 71 and 85</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Intact Parathyroid Hormone (iPTH) Levels</title>
          <population>All treated participants; only participants in the 5 mg/kg cohort were assessed at days 71 and 85</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="0.97"/>
                    <measurement group_id="O2" value="4.24" spread="0.70"/>
                    <measurement group_id="O3" value="4.93" spread="0.84"/>
                    <measurement group_id="O4" value="3.63" spread="0.62"/>
                    <measurement group_id="O5" value="3.77" spread="1.65"/>
                    <measurement group_id="O6" value="2.73" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="0.78"/>
                    <measurement group_id="O2" value="4.92" spread="0.78"/>
                    <measurement group_id="O3" value="5.01" spread="0.47"/>
                    <measurement group_id="O4" value="4.23" spread="0.54"/>
                    <measurement group_id="O5" value="3.50" spread="1.49"/>
                    <measurement group_id="O6" value="2.57" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.71"/>
                    <measurement group_id="O2" value="4.69" spread="0.69"/>
                    <measurement group_id="O3" value="5.38" spread="0.44"/>
                    <measurement group_id="O4" value="4.58" spread="0.76"/>
                    <measurement group_id="O5" value="3.50" spread="1.06"/>
                    <measurement group_id="O6" value="2.89" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="0.84"/>
                    <measurement group_id="O2" value="5.09" spread="0.69"/>
                    <measurement group_id="O3" value="5.09" spread="0.23"/>
                    <measurement group_id="O4" value="5.20" spread="1.13"/>
                    <measurement group_id="O5" value="3.93" spread="1.70"/>
                    <measurement group_id="O6" value="3.55" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="0.67"/>
                    <measurement group_id="O2" value="4.97" spread="0.93"/>
                    <measurement group_id="O3" value="5.75" spread="0.72"/>
                    <measurement group_id="O4" value="4.44" spread="0.77"/>
                    <measurement group_id="O5" value="3.82" spread="1.49"/>
                    <measurement group_id="O6" value="3.66" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="0.95"/>
                    <measurement group_id="O2" value="5.91" spread="0.86"/>
                    <measurement group_id="O3" value="5.23" spread="0.68"/>
                    <measurement group_id="O4" value="4.79" spread="0.90"/>
                    <measurement group_id="O5" value="4.14" spread="1.91"/>
                    <measurement group_id="O6" value="3.98" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="0.95"/>
                    <measurement group_id="O2" value="6.42" spread="0.59"/>
                    <measurement group_id="O3" value="5.46" spread="0.41"/>
                    <measurement group_id="O4" value="5.80" spread="0.61"/>
                    <measurement group_id="O5" value="4.19" spread="1.86"/>
                    <measurement group_id="O6" value="4.46" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="0.74"/>
                    <measurement group_id="O2" value="5.57" spread="0.64"/>
                    <measurement group_id="O3" value="6.15" spread="0.56"/>
                    <measurement group_id="O4" value="7.09" spread="0.84"/>
                    <measurement group_id="O5" value="5.46" spread="2.71"/>
                    <measurement group_id="O6" value="4.62" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="0.99"/>
                    <measurement group_id="O2" value="5.02" spread="0.74"/>
                    <measurement group_id="O3" value="5.92" spread="0.68"/>
                    <measurement group_id="O4" value="6.14" spread="0.72"/>
                    <measurement group_id="O5" value="4.83" spread="2.81"/>
                    <measurement group_id="O6" value="4.43" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="0.89"/>
                    <measurement group_id="O2" value="6.03" spread="0.73"/>
                    <measurement group_id="O3" value="5.27" spread="0.32"/>
                    <measurement group_id="O4" value="5.61" spread="0.84"/>
                    <measurement group_id="O5" value="3.93" spread="1.27"/>
                    <measurement group_id="O6" value="3.53" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="0.84"/>
                    <measurement group_id="O2" value="4.90" spread="0.64"/>
                    <measurement group_id="O3" value="4.87" spread="0.39"/>
                    <measurement group_id="O4" value="4.86" spread="0.55"/>
                    <measurement group_id="O5" value="2.76" spread="0.85"/>
                    <measurement group_id="O6" value="2.68" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="0.85"/>
                    <measurement group_id="O4" value="4.10" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="0.80"/>
                    <measurement group_id="O4" value="3.82" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)</title>
        <time_frame>Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)</title>
          <population>All treated participants</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.85" spread="6.39"/>
                    <measurement group_id="O2" value="59.23" spread="12.21"/>
                    <measurement group_id="O3" value="102.57" spread="18.26"/>
                    <measurement group_id="O4" value="196.37" spread="29.79"/>
                    <measurement group_id="O5" value="8.30" spread="1.78"/>
                    <measurement group_id="O6" value="164.44" spread="35.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)</title>
        <time_frame>Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)</title>
          <population>All treated participants</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.64" spread="1.40"/>
                    <measurement group_id="O2" value="-16.19" spread="7.36"/>
                    <measurement group_id="O3" value="-35.92" spread="1.94"/>
                    <measurement group_id="O4" value="-39.17" spread="5.13"/>
                    <measurement group_id="O5" value="-25.46" spread="8.52"/>
                    <measurement group_id="O6" value="-43.32" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Sclerostin</title>
        <time_frame>Baseline and days 12, 29, 43, 57, 71, and 85</time_frame>
        <population>All treated participants; only participants in the 5 mg/kg cohort were assessed at days 71 and 85.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Placebo</title>
            <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Women: Placebo</title>
            <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
          </group>
          <group group_id="O6">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Sclerostin</title>
          <population>All treated participants; only participants in the 5 mg/kg cohort were assessed at days 71 and 85.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.78" spread="3.72"/>
                    <measurement group_id="O2" value="6639.01" spread="534.50"/>
                    <measurement group_id="O3" value="13749.61" spread="1091.63"/>
                    <measurement group_id="O4" value="17028.81" spread="1875.81"/>
                    <measurement group_id="O5" value="-17.95" spread="6.38"/>
                    <measurement group_id="O6" value="14652.96" spread="1349.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="591.80" spread="596.47"/>
                    <measurement group_id="O2" value="1602.70" spread="231.77"/>
                    <measurement group_id="O3" value="7667.80" spread="675.45"/>
                    <measurement group_id="O4" value="12723.54" spread="2138.65"/>
                    <measurement group_id="O5" value="-14.54" spread="1.78"/>
                    <measurement group_id="O6" value="9581.13" spread="1283.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.43" spread="11.39"/>
                    <measurement group_id="O2" value="467.07" spread="55.62"/>
                    <measurement group_id="O3" value="3384.02" spread="613.99"/>
                    <measurement group_id="O4" value="6844.74" spread="1730.04"/>
                    <measurement group_id="O5" value="-9.35" spread="4.59"/>
                    <measurement group_id="O6" value="4487.33" spread="1771.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.89" spread="11.96"/>
                    <measurement group_id="O2" value="167.37" spread="28.33"/>
                    <measurement group_id="O3" value="911.23" spread="156.09"/>
                    <measurement group_id="O4" value="2836.61" spread="1109.97"/>
                    <measurement group_id="O5" value="-0.41" spread="12.65"/>
                    <measurement group_id="O6" value="1826.83" spread="917.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.80" spread="3.87"/>
                    <measurement group_id="O4" value="997.02" spread="532.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.41" spread="2.02"/>
                    <measurement group_id="O4" value="415.38" spread="243.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration of Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration of Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="12"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="5.0" lower_limit="5.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration of Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration of Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="1.45"/>
                    <measurement group_id="O2" value="17.1" spread="4.7"/>
                    <measurement group_id="O3" value="33.8" spread="8.1"/>
                    <measurement group_id="O4" value="18.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab</population>
          <units>µg*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="27.0"/>
                    <measurement group_id="O2" value="344" spread="90"/>
                    <measurement group_id="O3" value="804" spread="320"/>
                    <measurement group_id="O4" value="412" spread="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab</population>
          <units>µg*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" spread="26.8"/>
                    <measurement group_id="O2" value="347" spread="90"/>
                    <measurement group_id="O3" value="806" spread="323"/>
                    <measurement group_id="O4" value="421" spread="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) of Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab</population>
          <units>mL/day/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="10.0"/>
                    <measurement group_id="O2" value="9.27" spread="2.64"/>
                    <measurement group_id="O3" value="6.98" spread="2.35"/>
                    <measurement group_id="O4" value="7.91" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab with available T1/2,β data</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab with available T1/2,β data</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="15.1" spread="NA">Could not be calculated for 1 participant</measurement>
                    <measurement group_id="O3" value="16.2" spread="4.1"/>
                    <measurement group_id="O4" value="15.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab</title>
        <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
        <time_frame>Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese Women: Romosozumab 1 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O3">
            <title>Japanese Women: Romosozumab 5 mg/kg</title>
            <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
            <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab</title>
          <description>Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.</description>
          <population>All treated participants who received romosozumab</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="1.05"/>
                    <measurement group_id="O2" value="6.31" spread="1.14"/>
                    <measurement group_id="O3" value="7.19" spread="1.55"/>
                    <measurement group_id="O4" value="6.81" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Japanese Women: Placebo</title>
          <description>Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
        </group>
        <group group_id="E2">
          <title>Japanese Women: Romosozumab 1 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 1 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="E3">
          <title>Japanese Women: Romosozumab 3 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="E4">
          <title>Japanese Women: Romosozumab 5 mg/kg</title>
          <description>Japanese participants received a single subcutaneous injection of 5 mg/kg romosozumab on day 1.</description>
        </group>
        <group group_id="E5">
          <title>Non-Japanese Women: Placebo</title>
          <description>Non-Japanese participants received a single subcutaneous injection of placebo on day 1.</description>
        </group>
        <group group_id="E6">
          <title>Non-Japanese Women: Romosozumab 3 mg/kg</title>
          <description>Non-Japanese participants received a single subcutaneous injection of 3 mg/kg romosozumab on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Venomous sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

